NXP004, Nuformix’s potential anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF), led to a dose-dependent reduction in the production and deposition of proteins that are known key drivers of fibrosis (tissue scarring) and IPF progression, a preclinical study shows. Although these are preliminary findings in a tissue study,…
Early Data Support NXP004 as Potential IPF Treatment
Adelmidrol therapy reduced markers for inflammation and oxidative stress, as well as tissue damage and collagen deposits, in the lungs of mice with pulmonary fibrosis (PF), a study has found. The findings support further investigation of adelmidrol as a…
The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The initial phase of the five-year, $1-million #RAREis Scholarship Fund will include 32 scholarships — each totaling $5,000 —…
The world must learn to address our widespread anxiety about the ongoing health crisis. As a patient living with idiopathic pulmonary fibrosis (IPF), a life-threatening lung disease that makes me increasingly vulnerable to respiratory infections, I’m familiar with this anxiety. But life must continue, and it’s necessary to find a…
A gene therapy that lengthens the life of lung cells can halt scarring and help sustain lung regeneration in a mouse model of age-related pulmonary fibrosis, a new study shows. The study, “Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging,” was published in the Journal…
The nonprofit Three Lakes Foundation has teamed with Matter, a healthcare incubator, to launch the PF Innovation Challenge, an effort to promote better ways of diagnosing pulmonary fibrosis (PF) and caring for patients. Together, these Chicago-based groups set a total of $100,000 aside for the winning approaches. “Over the…
The first participant has been enrolled in a Phase 3 clinical trial evaluating Ofev (nintedanib) in children with fibrosing interstitial lung diseases (ILDs). The Phase 3 trial, called INPEDILD (NCT04093024), is sponsored by Boehringer Ingelheim, Ofev’s manufacturer. The trial is currently recruiting participants from 6–17 years…
I’ve been going through a second (Third? Fourth?) wave of grief for all things pre-pandemic. I am still mourning things that once brought me joy but are currently off-limits — rugby, concerts, being a wedding photographer, and date night out, to name a few things. I’m still hurting…
Treatment has commenced in a Phase 2 clinical trial investigating the safety and effectiveness of NP-120 (ifenprodil), Algernon Pharmaceuticals‘ experimental treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). IPF patients often experience a persistent, hard-to-treat cough, which affects…
During a video call with pulmonary fibrosis (PF) advocates last week, I was informed that the U.S. Eastern Seaboard faced some terrible weather. Severe thunderstorms left many without power for days. While this is inconvenient, a prolonged loss of power can be detrimental to the health of those requiring…
